Equities

Oncodesign Precision Medicine Opm SA

Oncodesign Precision Medicine Opm SA

Actions
  • Price (EUR)1.29
  • Today's Change-0.01 / -0.77%
  • Shares traded3.42k
  • 1 Year change+17.81%
  • Beta--
Data delayed at least 15 minutes, as of May 20 2024 10:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oncodesign Precision Medicine SA is a France-based biopharmaceutical company specialized in precision medicine. It aims at providing effective diagnostic and therapeutic solutions for resistant and metastatic cancers. The Company’s technologies from Oncodesign, are OncoSNIPER for the selection of therapeutic targets using artificial intelligence; Nanocyclix for the design and selection of macrocyclic small molecule kinase inhibitors and Theranostics for the design and selection of radiolabeled biological molecules for systemic radiotherapy. It focuses on the research and development of therapeutic and diagnostic solutions in the clinical and preclinical areas of medical oncology.

  • Revenue in EUR (TTM)1.07m
  • Net income in EUR-8.09m
  • Incorporated2020
  • Employees22.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Acticor Biotech SA0.00-18.65m15.13m24.00--32.19-----1.68-1.680.000.02980.00----0.00-145.59---297.22-------------9.320.9504-------25.94------
Ikonisys SA538.56k-2.40m15.47m11.00--0.8463--28.72-0.2499-0.24990.0561.750.02461.146.2048,960.00-10.94---12.55--2.72---444.76--0.0818-36.790.1007--68.94---328.57------
Plant Advanced Technologies PAT SA2.34m-849.00k16.54m56.00--2.24--7.07-0.7853-0.78532.156.700.13680.98692.8741,767.86-4.91-3.18-7.20-4.0422.8398.91-35.87-27.900.8691-16.730.4472--1.4823.7225.13--3.57--
Valerio Therapeutics SA1.80m-20.34m16.70m19.00--1.13--9.28-0.1566-0.15660.01330.09610.0459--1.0794,736.84-51.92-34.19-67.72-40.5970.3984.11-1,130.22-586.99---171.660.3776--24.74-21.73-4.00--32.39--
SMAIO SA7.62m1.06m17.99m37.0016.881.667.562.360.20380.20381.462.070.56240.187117.23206,027.607.81-7.8710.24-19.7696.9596.0413.89-22.482.5411.070.1991--212.18114.99-62.80------
Phaxiam Therapeutics SA1.33m-23.49m18.56m51.00--0.7246--14.00-5.56-5.560.31394.220.0273--14.8226,000.00-48.37-50.69-66.94-66.25-----1,771.42-1,009.09---70.210.3412---80.05-21.50-10,201.75---56.68--
NicOx SA3.57m-17.36m18.61m11.00--0.4054--5.21-0.3721-0.37210.07530.91280.0394--1.83324,909.10-19.13-19.22-21.35-20.78-----485.70-370.14----0.3172---54.787.2536.57---13.35--
Nfl Biosciences SAS0.00-3.48m20.96m3.00--5.32-----0.5396-0.53960.000.40970.00----0.00-80.79---125.59--------------0.0228-------149.78------
Oncodesign Precision Medicine Opm SA1.07m-8.09m23.65m22.00--5.86--22.06-0.4863-0.48630.06450.22190.0613--1.3948,735.00-46.23---63.87--130.48---754.61------0.7052---86.57---3,399.73------
Advicenne SA2.37m-10.39m26.13m25.00------11.04-1.03-1.030.2342-1.400.19386.101.9494,680.00-85.09-46.00-178.65-61.82-204.18-441.10-438.99-597.560.8356-6.224.33---12.3233.267.70--26.86--
Predilife SA317.79k-4.22m26.41m19.00------83.12-1.14-1.140.0858-1.060.0695--2.0517,030.55-92.43-89.36-129.39-123.8197.2583.94-1,329.21-1,901.22---6.232.20--10.1179.85-15.58---18.51--
Poxel SA1.55m-44.24m29.68m30.00------19.20-1.44-1.440.0507-1.220.0597--5.4230,920.00-170.71-31.97-432.50-55.940.1294---2,861.58-101.47---4.0811.28---94.97-33.77-32.13---8.49--
Global Bioenergies SA3.25m-8.66m33.19m46.00--3.19--10.22-0.4797-0.47970.18020.57430.16325.2165.6270,638.05-43.47-43.66-64.54-82.47-153.20-948.35-266.41-1,331.363.54--0.2626--365.8336.2527.78---19.49--
Fermentalg SA4.06m-14.15m33.24m62.00--1.02--8.19-0.3176-0.31760.09170.60330.07530.5333.3565,451.61-24.63-21.94-26.79-24.7113.2114.73-327.08-248.953.53-60.940.3323---46.9475.18-43.29---10.93--
Abionyx Pharma SA4.64m-3.52m35.38m61.00--4.43--7.63-0.121-0.1210.15810.2460.302721.864.2076,694.22-22.95-18.82-32.52-28.8713.3214.32-75.82-128.541.70--0.2997---11.6592.8416.36--41.40--
Data as of May 20 2024. Currency figures normalised to Oncodesign Precision Medicine Opm SA's reporting currency: Euro EUR

Institutional shareholders

1.32%Per cent of shares held by top holders
HolderShares% Held
OFI Invest Asset Management SAas of 29 Feb 2024158.04k0.87%
Claresco Finance SAas of 30 Jun 202367.80k0.37%
Gestys SAas of 23 Feb 202414.00k0.08%
Data from 30 Jun 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.